Compare NVRI & DCTH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | NVRI | DCTH |
|---|---|---|
| Founded | 1853 | 1988 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Diversified Commercial Services | Medical/Dental Instruments |
| Sector | Miscellaneous | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 582.1M | 578.4M |
| IPO Year | 2026 | 2015 |
| Metric | NVRI | DCTH |
|---|---|---|
| Price | $22.35 | $16.35 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $22.00 |
| AVG Volume (30 Days) | 340.9K | ★ 702.7K |
| Earning Date | 05-14-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 107.53 |
| EPS | N/A | ★ 0.04 |
| Revenue | N/A | N/A |
| Revenue This Year | $3.87 | $24.54 |
| Revenue Next Year | $3.70 | $33.15 |
| P/E Ratio | ★ N/A | $409.75 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $10.81 | $8.12 |
| 52 Week High | $24.20 | $17.42 |
| Indicator | NVRI | DCTH |
|---|---|---|
| Relative Strength Index (RSI) | 56.37 | 58.70 |
| Support Level | $17.79 | $8.57 |
| Resistance Level | $23.77 | $17.42 |
| Average True Range (ATR) | 1.18 | 0.54 |
| MACD | 0.24 | -0.15 |
| Stochastic Oscillator | 74.65 | 14.96 |
Enviri Corp provides environmental and operational solutions to the metal and rail industries. It is based in Philadelphia, Pennsylvania, and operates in more than 30 countries. The company leverages industrial expertise to help customers improve operational performance, recover value from byproducts, enhance sustainability, and maintain critical infrastructure. Its divisions are Harsco Environmental and Harsco Rail, which combine deep operational capabilities with technologies and world-wide scale to deliver long-term value for customers, communities, and shareholders.
Delcath Systems Inc is an oncology company. The company is focused on the treatment of primary and metastatic liver cancers. The firm's product include Melphalan Hydrochloride, Hepzato for Injection along with the Delcath Hepatic Delivery System, or Melphalan/HDS, is a drug and device combination product, designed to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects. The company operates in one reportable segment which includes the research, development, manufacture, and distribution of hepatic delivery systems for use in the treatment of specific conditions. The Company operates its business in the United States and Europe.